{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kuang Z"],"funding":["the National Key Research and Development Program of China"],"pagination":["939-950"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11027608"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["69(6)"],"pubmed_abstract":["With the great success of anti-CTLA-4 and anti-PD-1 therapeutics in cancer immunotherapy, tumor necrosis factor receptor superfamily members have been recognized as ideal targets to provide co-stimulatory signals in combination with immune checkpoint blocking antibodies. Among these is OX40 (CD134), a co-stimulatory molecule expressed by activated immune cells. Recently, several anti-OX40 agonistic monoclonal antibodies, pogalizumab as the most advanced, have entered early phase clinical trials. Using a yeast platform and multiple screening methods, we identified a fully human anti-OX40 antibody (IBI101) with distinct modes of action. Unlike pogalizumab, IBI101 partially blocks the binding of OX40 to its ligand OX40L and exhibits both FcγR-dependent and independent agonistic activities in "],"journal":["Cancer immunology, immunotherapy : CII"],"pubmed_title":["Development and characterization of a novel anti-OX40 antibody for potent immune activation."],"pmcid":["PMC11027608"],"funding_grant_id":["2017YFC0909801"],"pubmed_authors":["Jing H","Baruah H","Wu M","Liu J","Prinz B","Yu M","Ni H","Zhou S","Wu D","Wang J","Chen B","Kuang Z","Zhang P","Wu Z","Li Y","Qiu X","Wu W"],"additional_accession":[]},"is_claimable":false,"name":"Development and characterization of a novel anti-OX40 antibody for potent immune activation.","description":"With the great success of anti-CTLA-4 and anti-PD-1 therapeutics in cancer immunotherapy, tumor necrosis factor receptor superfamily members have been recognized as ideal targets to provide co-stimulatory signals in combination with immune checkpoint blocking antibodies. Among these is OX40 (CD134), a co-stimulatory molecule expressed by activated immune cells. Recently, several anti-OX40 agonistic monoclonal antibodies, pogalizumab as the most advanced, have entered early phase clinical trials. Using a yeast platform and multiple screening methods, we identified a fully human anti-OX40 antibody (IBI101) with distinct modes of action. Unlike pogalizumab, IBI101 partially blocks the binding of OX40 to its ligand OX40L and exhibits both FcγR-dependent and independent agonistic activities in ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jun","modification":"2025-04-22T20:45:52.187Z","creation":"2025-04-06T03:15:03.373Z"},"accession":"S-EPMC11027608","cross_references":{"pubmed":["32078015"],"doi":["10.1007/s00262-020-02501-2"]}}